OVERVIEW | FOUNDING DIRECTORS | CORPORATE DIRECTORY | STATUTORY DETAILS

  
 
Founding Directors

Dr. Roger New
Co-Founder

Roger is a co-founder of Proxima Concepts, Infexion’s parent company. Roger has extensive experience with oral drug delivery technologies for proteins and peptides having served as head of research at Cortecs. Roger also spent a large part of his career with the Liverpool School of Tropical Medicine and is an internationally recognized expert on liposomes.
  • Thirty years experience of Research and Development in field of drug delivery
  • World-recognised expert in liposomes: author of seminal reference book “Liposomes - A Practical Approach” published by OUP
  • First to demonstrate efficacy of liposomal amphotericin. Coordinated first Phase I/II trials of liposomal doxorubicin
  • Devised three new systems for oral delivery of insulin, giving first positive human results ever observed in Type I diabetics
  • Honorary professor at several foreign academic institutions. Consultant advisor to IRCD. Member of UK Govt Expert Mission on Biotechnology to China
  • Patent applications filed and granted in areas of pharmaceutics, diagnostics and microbiology
  • Inventor of Mozaic


Mr. Glen Travers
Co-Founder

Glen is a co-founder of Proxima Concepts. Glen was also a founder and CEO of Western Capital, a private equity firm established in 1985. Glen became Chairman of Cortecs Ltd., the UK subsidiary of Western Capital, in 1989 and served as Executive Chairman from 1992 to 1998. During that time, Cortecs International PLC became a global leader in oral drug delivery systems for proteins and peptides and was listed on the UK and Nasdaq exchanges.
Achievements as founder and chief executive in biopharmaceutical arena:

  • Developed and launched ‘89 first helicobacter diagnostic - CLOTEST
  • Licensed to Upjohn for USA- Royalties received for 10 years
  • Developed and launched first Hp point of care diagnostic - HELISAL
  • Launched with Astra in UK, Boehringer Mannheim ROW, Becton Dickinson USA
  • Developed and launched with Ciba animal care antibacterial DETACH in Australia
    Developed and launched first oral mucosal vaccine – BRONCOSTAT, sold to RPR 1990
  • Developed first point-of-care osteoporosis diagnostic ‘98 - OSTEOSAL
  • Developed first point-of-care HBA1c diagnostic ‘98 – GLYCOSAL
  • Founded and built biopharmaceutical company to peak $1.2bn value ($0.5bn on departure)
  • Listed company in UK, Australia, Nasdaq, and developed £7m turnover for UK pharmaceutical distribution
  • Registered new products with FDA, MCA
  • Developed collaborations with 12 Universities including Centre for Vaccine Development at Cambridge University
  • European Healthcare Entrepreneur of the Year 1996 sponsored by Ernst & Young and Atlas Ventures